档案库 · 医疗与健康 · 战略决策 · 2025
Onward Medical 的无预存设备豪赌：非侵入性脊髓治疗首获 FDA 批准
Onward 赢得 FDA 首个非侵入性脊髓刺激器 de novo 授权，随后一年内将 ARC-EX 从诊所拓展至家庭使用。
Onward Medical
做的是什么生意
Onward Medical, a Netherlands-based publicly traded medical device company, sells the ARC-EX System: an external stimulator and wireless programmer that deliver programmed electrical stimulation through electrodes placed on the back of the neck, improving hand strength and sensation after spinal cord injury without surgery.
起因
Traditional spinal cord stimulation devices require surgery to implant electrodes, leaving a gap for the far larger population living with chronic spinal cord injuries who could benefit from non-invasive therapy. Because no predicate device existed for that approach, Onward could not file a routine 510(k) showing equivalence; it had to pursue FDA's de novo classification, which demands clinical evidence that a novel device is safe and effective enough to create a new regulatory category.
经过
Onward ran the Up-LIFT study, published in Nature Medicine, which reported that 90% of participants improved in strength or function and 87% reported higher quality of life, with benefits including reduced spasm frequency and improved sleep observed in people whose injuries dated back as long as 34 years. On 2025-01-06 the FDA granted de novo classification and market authorization for ARC-EX as the first technology approved to enhance hand strength and sensation after chronic spinal cord injury. Eleven months later, on 2025-11-17, a 510(k) clearance expanded the indication so adults with incomplete spinal cord injuries at levels C2-C8 could use the system for functional task practice in the clinic and take-home exercises at home.
结果
Two regulatory approvals in eleven months converted ARC-EX from a breakthrough device into a reimbursable, repeatable therapy: the de novo authorization opened US commercial sales, and the home-use clearance let Onward widen from clinic-administered sessions to therapy patients continue themselves, with more than 60 US clinics offering the system within its first year.
背景
Onward Medical 是一家荷兰医疗器械公司，押注慢性脊髓损伤的非侵入性治疗。其 ARC-EX 系统通过外部刺激器向颈背电极输送程序化电刺激，不同于需要手术植入的传统脊髓刺激设备——由于非侵入性方法无预存设备，公司必须创建监管类别，而非声称与已批准产品等效。
Onward 采用 FDA 针对中低风险新型设备的 de novo 路径，并以发表于《自然·医学》的 Up-LIFT 临床研究为支撑：90% 参与者力量或功能改善，87% 报告生活质量提高，痉挛频率降低、睡眠改善等益处甚至出现在伤后长达 34 年的患者中。2025-01-06，FDA 授予 de novo 分类和市场授权，使 ARC-EX 成为首个获 FDA 批准、证明可改善慢性脊髓损伤后手部力量和感觉的技术。
第二幕发生在 2025-11-17：510(k) 许可扩大了 ARC-EX 适应症，允许 C2-C8 不完全脊髓损伤、慢性非进行性缺损的成年人在家使用。商业可用不到一年，系统已进入 60 多家美国诊所，新标签让治疗从监督会话转向居家锻炼——将 Onward 的市场从诊所扩展到患者家中。
这件事要成立，得有什么
- 非侵入性疗法无预存设备，Onward 进入美国市场的唯一途径是 FDA 的 de novo 路径，要求公司证明设备足够安全以定义新类别。
- Up-LIFT 试验提供了证据：发表结果——90% 参与者改善，87% 报告生活质量提高——给了监管者授权新型设备类别的依据。
- 诊所优先推出是有意为之：监督会话产生了真实使用和报销牵引力，为 Onward 争取更广泛家用适应症创造了记录。
- 从诊所扩展到家庭成倍扩大了市场，让人们每天继续功能性任务治疗，而非仅在就诊时——将专科程序转变为持续产品。
可借鉴之处
当无设备存在时，监管者定义市场：de novo 胜利创造了类别，而家用许可表明赢得新标签只是扩大规模的第一步。
后续进展
截至 2025-11-17，Onward Medical 在十一个月内获得两项 ARC-EX 的 FDA 批准：2025 年 1 月的 de novo 市场授权使其成为首个 FDA 批准的非侵入性改善慢性脊髓损伤后手部力量和感觉的技术，以及 2025 年 11 月的 510(k) 许可允许家庭使用。CEO Dave Marver 称首个授权是慢性脊髓损伤患者新时代的开始，公司正将商业可用性扩大到已提供系统的 60 多家美国诊所之外。
资料来源
- ONWARD Medical receives FDA authorization for its spinal cord stimulation system
- ONWARD Medical Secures FDA Clearance For ARC-EX System Home Use
发现哪里写错了？告诉我们。
轮到你了
你刚读完一家。说说你在做什么，看看谁在赌同一件事。
免费账号 · 3 次免费提问 · 不用绑卡